EASD 2017

New insights into global diabetes management at EASD 2017

 

The DISCOVER team presented exciting baseline data at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD), Lisbon, Portugal,11–15 September.

 

Metformin discontinuation

DISCOVER reveals new trends in metformin discontinuation in 11 452 patients – EASD 2017

 

Professor Kamlesh Khunti of the DISCOVER Scientific Committee presented an exciting new analysis of metformin discontinuation from the DISCOVER study at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD) on 11–15 September in Lisbon, Portugal.

 

Reality versus guidelines

New trends of treatment reality versus guidelines from 32 countries presented at EASD 2017

 

Dr Marilia Gomes of the DISCOVER Scientific Committee presented an exciting new analysis of treatment reality versus guidelines from the DISCOVER study at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD), 11–15 September in Lisbon, Portugal.

 

The DISCOVER study

 

DISCOVER is a global, prospective, observational study of patients with type 2 diabetes who are starting second-line glucose-lowering therapy. The study has enrolled over 15 000 patients in 38 countries across six continents, and will provide a comprehensive and contemporary picture of treatment patterns and outcomes in patients with type 2 diabetes worldwide.

 

Type 2 diabetes and real world evidence

 

The DISCOVER study is designed to generate real world evidence (RWE) about people living with type 2 diabetes across the globe. RWE is key to understanding more about type 2 diabetes and how it is managed in day-to-day clinical practice, and therefore contributes to improved disease management.

 

DISCOVER publications

 

The DISCOVER study will provide unprecedented global insights into the treatment of type 2 diabetes. The DISCOVER Scientific Committee is planning a series of abstracts, posters, presentations and journal articles about the DISCOVER study design and results at global, regional and local levels.

 

The DISCOVER study

The DISCOVER study

 

DISCOVER is a global, prospective, observational study of patients with type 2 diabetes who are starting second-line glucose-lowering therapy. The study has enrolled over 15 000 patients in 38 countries across six continents, and will provide a comprehensive and contemporary picture of treatment patterns and outcomes in patients with type 2 diabetes worldwide.

 
 

Type2 diabetes and real world evidence

Type 2 diabetes and real world evidence

The DISCOVER study is designed to generate real world evidence (RWE) about people living with type 2 diabetes across the globe. RWE is key to understanding more about type 2 diabetes and how it is managed in day-to-day clinical practice, and therefore contributes to improved disease management.

 

DISCOVER publications

DISCOVER publications

 

The DISCOVER study will provide unprecedented global insights into the treatment of type 2 diabetes. The DISCOVER Scientific Committee is planning a series of abstracts, posters, presentations and journal articles about the DISCOVER study design and results at global, regional and local levels.